The supplemental New Drug Application from BeiGene Ltd. (BGNE) for the expansion of its blockbuster drug Brukinsa to a fifth indication is currently under FDA review, with a decision due this quarter.This time, the company is seeking FDA approval for Brukinsa in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after at least two prior lines of therapy.The drug is already approved for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, Waldenström’s macroglobulinemia, mantle cell lymphoma who have received at least one prior therapy, and relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.The global sales of Brukinsa were $1.3 billion for full year 2023, compared to $564.7 million in 2022.BGNE closed Tuesday's (Feb.27, 2024) trading at $179.69, up 12.12%.